Drug Safety’s “Equal Voice” To Be Considered At Internal CDER Workshop
Executive Summary
Review staff from the Center for Drug Evaluation and Research will meet in December to discuss how to implement the concept of giving an "equal voice" to safety personnel during regulatory decision-making
You may also be interested in...
CDER Eyes Prioritization, Timely Resolution Of Post-Marketing Safety Issues
Now that it has a system in place to track post-marketing drug safety issues, FDA’s Center for Drug Evaluation and Research is turning its attention to setting standard timeframes for investigating and addressing such signals.
CDER Eyes Prioritization, Timely Resolution Of Post-Marketing Safety Issues
Now that it has a system in place to track post-marketing drug safety issues, FDA’s Center for Drug Evaluation and Research is turning its attention to setting standard timeframes for investigating and addressing such signals.
The REMS Report Card: FDA Using New Tools For One-Third Of New Drugs In First Six Months
FDA has used its new authority to impose a Risk Evaluation and Mitigation Strategy on roughly one-third of all new molecular entities approved since the REMS provisions of the FDA Amendments Act took effect at the end of March.